$55.49▾ 1.65%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-60.39MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+74.2%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
✦ The read
Global X Genomics & Biotechnology ETF is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year. A modest, well-covered debt load.
Key numbers
Profitability
Net margin-355.2%
TTM (trailing 12 months, through fiscal Q3 FY2012)
Size
Revenue (TTM)$22.35M
TTM (trailing 12 months, through fiscal Q3 FY2012)
Signals and key numbers are from the fiscal Q3 FY2012 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.